The Use of Secukinumab in Psoriatic Patients: A Single Center Study in Morocco

Meryem Elomari Alaoui *

Department of Dermatology and Venerology, University Hospital Center Ibn SINA, University Mohamed V, Rabat, Morocco.

Amani Fliti

Department of Dermatology and Venerology, University Hospital Center Ibn SINA, University Mohamed V, Rabat, Morocco.

Mariame Meziane

Department of Dermatology and Venerology, University Hospital Center Ibn SINA, University Mohamed V, Rabat, Morocco.

Nadia Ismaili

Department of Dermatology and Venerology, University Hospital Center Ibn SINA, University Mohamed V, Rabat, Morocco.

Laila Benzekri

Department of Dermatology and Venerology, University Hospital Center Ibn SINA, University Mohamed V, Rabat, Morocco.

Karima Senouci

Department of Dermatology and Venerology, University Hospital Center Ibn SINA, University Mohamed V, Rabat, Morocco.

*Author to whom correspondence should be addressed.


Abstract

Introduction: Psoriasis is an immune cell-mediated inflammatory skin disease, characterized by the formation of scaly, indurated, erythematous plaques. Psoriasis comorbidities and symptoms affect the choice of treatments. Secukinumab is a fully human monoclonal anti-body that selectively neutralizes IL-17A and has proven to be effective in the treatment of multiple manifestations of psoriatic disease.

Materials and Methods: In this prospective descriptive study of 13 patients with moderate to severe psoriasis in the Department of Dermatology at Ibn Sina University Hospital in Rabat between 2022 and 2024, we focus on the treatment of psoriasis with Secukinumab. All our patients received more than 6 injections of Secukinumab. Effectiveness was assessed using the change in absolute Psoriasis Area and Severity Index (PASI) score, and percentage of patients achieving PASI 75/90/100, at weeks 4 and 16.

Results: In this study, 13 patients with severe psoriasis with a PASI>10 were included. The mean age at diagnosis was 44.7 years and the mean duration of the disease before diagnosis was 5 years. All our patients received Secukinumab following this protocol (subcutaneous injection of 300mg at weeks 0,1,2,3 and 4, followed by 300mg every 4 weeks) and the PASI 75, PASI 90, PASI 100 was evaluated respectively.

At week 4, 69.2% of patients still on Secukinumab had experienced at least a 50% reduction in PASI (PASI 50) from baseline. At week 16, the proportions of patients achieving PASI 75, PASI 90, and PASI 100 were: 23,1%, 30,7%, (46,2%) respectively.

Adverse events possibly relevant to Secukinumab therapy were not reported in our patients

Conclusion: To improve the quality of life of psoriatic patients, the choice of available treatments is now increasing. Secukinumab showed sustained effectiveness and favorable safety profile in patients with moderate to severe psoriasis in our patients.

Keywords: Psoriasis, inflammatory, secukinumab, PASI


How to Cite

Alaoui, M. E., Fliti , A., Meziane , M., Ismaili , N., Benzekri , L., & Senouci , K. (2024). The Use of Secukinumab in Psoriatic Patients: A Single Center Study in Morocco. Asian Journal of Research in Dermatological Science, 7(1), 14–18. Retrieved from https://journalajrdes.com/index.php/AJRDES/article/view/100

Downloads

Download data is not yet available.

References

Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis. JAMA. 2020;323(19):1945. [PubMed] [Google Scholar]

Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2016;31(2):205‐212. [PubMed] [Google Scholar]

Martínez‐Ortega JM, Nogueras P, Muñoz‐Negro JE, Gutiérrez‐Rojas L, González‐Domenech P, Gurpegui M. Quality of life, anxiety and depressive symptoms in patients with psoriasis: A case‐control study. J Psychosom Res. 2019;124:109780. [PubMed] [Google Scholar]

Thakolwiboon S, Upala S, Geeratragool T et al. The factors affecting quality of life in Thai psoriasis patients. J Med Assoc Thai. 2013;96(10):1344‐1349. [PubMed] [Google Scholar]

Unaeze J, Nijsten T, Murphy A, Ravichandran C, Stern RS. Impact of psoriasis on health‐related quality of life decreases over time: An 11‐year prospective study. J Invest Dermatol. 2006;126(7):1480‐1489. [PubMed] [Google Scholar]

Menter A, Strober BE, Kaplan DH et al. Joint AAD‐NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029‐1072. [PubMed] [Googl Scholar]

Sanford M, McKeage K. Secukinumab: First global approval. Drugs. 2015;75(3):329‐338. [PubMed] [Google Scholar]

Rønholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. 2017;18(11):2297 [PMC free article][PubMed] [Google Scholar]

Asawanonda P, Pattamadilok B, Chularojanamontri L, Chuamanochan M, Choonhakarn C, Chakkavittumrong P, Sangob N, Rajatanavin N. Real-world experience of secukinumab in moderate to severe psoriasis patients in Thailand: Characteristics, effectiveness, and safety. Dermatol Ther. 2022 Dec;35(12):e15958. DOI: 10.1111/dth.15958. Epub 2022 Nov 16. PMID: 36279306; PMCID: PMC10078165.

Furue K, Ito T, Tsuji G, Kadono T, Furue M. Psoriasis and the TNF/IL23/IL17 axis. G Ital Dermatol Venereol. 2019 Aug;154(4):418-424. DOI: 10.23736/S0392-0488.18.06202-8. Epub 2019 Jan 15. PMID: 30648836.

Griffin L, Boggs J, Ramsay B, Hackett C, Ahmad K, Lynch M. Practical experience of secukinumab in the treatment of psoriasis: Experience from a single centre. Irish Journal of Medical Science (1971 -); 2020. DOI:10.1007/s11845-020-02336-x

Kim BS, Kim DH, Shin BS, Lee ES, Jo SJ, Bang CH, Yun Y, Choe YB. Real-world safety and effectiveness of secukinumab in adult patients with moderate to severe plaque psoriasis: Results from postmarketing surveillance in Korea. Ther Adv Chronic Dis. 2024 Feb 26;15:20406223241230180.

DOI: 10.1177/20406223241230180. PMID: 38415046; PMCID: PMC10898308.

Schwensen JF, Clemmensen A, Sand C et al. Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multi- center study. Dermatologic Therapy. 2017;e12550. Available:https://doi.org/10.1111/dth.12550

Foley P, Tsai T‐F, Rodins K et al. Effectiveness and safety of secukinumab for psoriasis in a real‐world clinical setting in the Asia‐Pacific and Middle East regions: results from the REALIA study. Dermatol Ther. 2022;12(2):511‐527. [PMC free article] [PubMed] [Google Scholar]

Fujita H, Ohtsuki M, Morita A et al. Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real‐world evidence in Japan. J Dermatol. 2020;48(2):175‐183. [PMC free article [PubMed] [Google Scholar]

Zhao Y, Cai L, Liu X‐Y, Zhang H, Zhang J‐Z. Efficacy and safety of secukinumab in Chinese patients with moderate‐to‐severe plaque psoriasis: A real‐life cohort study. Chin Med J. 2021;134(11):1324‐1328. [PMC free article] [PubMed] [Google Scholar]

Caldarola G, Mariani M, Pirro F et al. Comparison of short‐ and long‐term effectiveness of ixekizumab and secukinumab in real‐world practice. Expert Opin Biol Ther. 2021;21(2):279‐286. [PubMed] [Google Scholar]

Langley RG, Sofen H, Dei-Cas I, Reich K, Sigurgeirsson B, Warren RB, Paul C, Szepietowski JC, Tsai TF, Hampele I, You R, Charef P, Papavassilis C. Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials. Br J Dermatol. 2023 Feb 10;188(2):198-207 DOI:10.1093/bjd/ljac040. PMID: 36763857.

Penso L, Dray-Spira R, Weill A, Pina Vegas L, Zureik M, Sbidian E. Association Between Biologics Use and Risk of Serious Infection in Patients With Psoriasis. JAMA Dermatol. 2021 Sep 1;157(9):1056-1065.

DOI: 10.1001/jamadermatol.2021.2599. PMID: 34287624; PMCID: PMC8295892.

18-Bissonnette R, Luger T, Thaci D et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018;32(9): 1507–1514.

DOI: 10.1111/jdv.14878 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Kirkham BW, Kavanaugh A, Reich K. Interleukin‐17A: A unique pathway in immune‐mediated diseases: Psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology. 2014;141(2):133‐142. [PMC free article] [PubMed] [Google Scholar]